Human Genome Sciences
reported a wider loss in the third quarter, but brought in better revenue than Wall Street expected.
The biopharmaceutical company lost $60.8 million, or 46 cents a share, in the latest quarter. The results include $6.4 million, or 5 cents a share, in stock-based compensation expenses.
For the same period a year ago, Human Genome lost $54.4 million, or 42 cents a share. In 2005, stock-based compensation costs weren't recognized.
Human Genome's revenue exceeded expectations, coming in at $6.7 million in the third quarter, compared with analysts' estimates of $5.93 million. The company had a top line of $5.9 million a year ago.
Revenue included a $2.6 million upfront payment from
for its partnership involving the hepatitis C drug Albuferon, a $1.1 million payment from
for the co-development of the lupus drug LymphoStat-B, and a $1 million payment from Glaxo for the initiation of clinical trials on a sleep-disorder drug.
Shares of Human Genome fell 2% to $13.55 Wednesday morning.